Kypha seeks to discover, develop and commercialize innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space. Our plan is for these tests to become standard of care, having application across a wide range of indications.
There are many ways that the human body can be harmed, physical injury such as head trauma during a sport, or illness like a bacterial infection. The body’s immune system’s response is similar to both, initiating beneficial inflammation.
Kypha’s business thesis is based on the premise that there is huge untapped clinical and commercial potential for complement diagnostics.
This job’s for you: 9 researcher-proven tips for scientists seeking a new career https://www.uab.edu/mix/stories/this-job-s-for-you-9-researcher-proven-tips-for-scientists-seeking-a-new-career
The Complement system is one of the longest-studied biological systems in the body, and despite decades of attempts to tap into its clinical potential – both therapeutically and diagnostically – most of that potential remains unrealized.
When we founded Kypha, we understood it would take a significant effort – collaborative in nature – to realize our goal of capturing the full clinical potential of complement diagnostics. Over the past 4 years that has been our focus. We have collaborated extensively and built a “Center of Excellence” around complement diagnostics in order to facilitate that Mission. We believe the reward will be well worth it – to patients, clinicians, researchers, hospitals and healthcare, as well as all of our collaborators and Kypha stakeholders.
Chad M. Stiening, PhD Kypha CEO